Monoclonal antibody provides strong real-world protection against severe RSV in infants, suggests meta-analysis

Nirsevimab, a monoclonal antibody, is highly effective in real-world conditions at preventing severe respiratory syncytial virus (RSV) infections in infants, suggests a meta-analysis published in The Lancet Child & Adolescent Health journal.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup